Generalized data of criteria of risk factors for the use of the drug torasemide from the materials of its preclinical studies

Abstract


Thе article reviewed, analyzed and summarized the results of experimental (preclinical) pharmacological studies of the drug Torsemide. Torsemide is the first of the new generation of loop diuretics, which fundamentally differs from the first generation of loop diuretics in the spectrum of pharmacological effects.

The present review considers safety aspects, pharmacokinetics, pharmacodynamics of Torsemide found in various studies in preclinical research. Information on the effectiveness of Torsemide- based preparations in the treatment of chronic heart failure and arterial hypertension is given in the relevant sections of the article.

The search for information sources for the review was carried out using domestic and international databases elibrary and PubMed, applying contextual queries, including international non-proprietary names, terms of preclinical studies of pharmacokinetics, pharmacodynamics, and animal species used.

The summarized data presented in the study, in our opinion, may be used by researchers who are engaged in preclinical and clinical studies, as well as the issues of studying the efficacy and safety of generic drugs used in the treatment of patients with arterial hypertension and other cardiovascular pathology.


About the authors

Natalia A. Anisimova

Saint Petersburg State Chemical and Pharmaceutical University, Saint Petersburg, Russia

Email: natalia.anisimova@pharminnotech.com

Russian Federation, 197376, St. Petersburg, Professora Popova st., 14

PhD in Biological Sciences at the Department of Pharmacology and Clinical Pharmacology

Natalia O. Selizarova

Saint Petersburg State Chemical and Pharmaceutical University, Saint Petersburg, Russia

Email: selizarova@pharminnotech.com

Russian Federation, 197376, St. Petersburg, Professora Popova st., 14

PhD in Medicine at the Department of Pharmacology and Clinical Pharmacology

Grigory A. Plisko

Saint Petersburg State Chemical and Pharmaceutical University, Saint Petersburg, Russia

Email: grigoriy.plisko@pharminnotech.com

Russian Federation, 197376, St. Petersburg, Professora Popova st., 14

Junior Researcher, Center for Experimental Pharmacology

Evgeny D. Semivelichenko

Saint Petersburg State Chemical and Pharmaceutical University, Saint Petersburg, Russia

Email: evgeniy.semivelichenko@pharminnotech.com
197376, St. Petersburg, Professora Popova st., 14

Junior Researcher, Center for Experimental Pharmacology

Svetlana M. Napalkova

Saint Petersburg State Chemical and Pharmaceutical University, Saint Petersburg, Russia

Author for correspondence.
Email: svetlana.napalkova@pharminnotech.com

Russian Federation, 197376, St. Petersburg, Professora Popova st., 14

PhD in Biological Sciences, Professor, Professor at the Department of Pharmacology and Clinical Pharmacology

References

  1. Delarge J, Lapière CL A new class of high ceiling diuretics :derivatives of 1-alkyl-3-(4-phenylaminopyridin-3-yl)sulfonylurea (author'stransl)// AnnPharmFr. 1978; 36 (7-8):369-79.
  2. Dunn C.J., Fittion A., Broglen R.N. Torasemide. Review of its pharmacology and therapeutic use. Drugs1995; 49:121—142.
  3. Диагностика и лечение артериальной гипертензии. Рекомендации РМОАГ и ВНОК 2010 (четвертый пересмотр). Системные гипертензии 2010; 3:5 – 26.
  4. Подзолков В.И., Можарова Л.Г., Хомицкая Ю.В. Артериальная гипертензия у женщин с климактерическим синдромом. Обзоры клин. кардиол. 2005; 4: 35–42.
  5. Ткачева О.Н., Шарашкина Н.В., Новикова И.М. и др. Сравнительное исследование эффектов торасемида и гипотиазида в комбинированном лечении гипертонической болезни у женщин в период постменопаузы. Сердце 2011; 3: 156–160.
  6. Кириченко А.А. Петлевые диуретики в практике терапевта. CONSILIUM MEDICUM (Кардиология) 2011; 1: 58–63.
  7. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Сердеч. недостат. 2010; 11: 3–62.
  8. Азизова А.Г., Овчинников А.Г., Агеев Ф.Т. Сравнительное влияние торасемида и фуросемида на клинический статус и диастолическую функцию левого желудочка. Сердеч. недостат. 2011; 12: 326–332.
  9. Lopez B., Querejrta R., Gonzalez A. et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028–2035.
  10. Tanaka H., Vatanabe K., Harima M. et al. Effects of various diuretics on cardiac function in rats with heart failure. Yakugaku Zasshi 2009;129: 871–879.
  11. Фомин В.В. Свойства антагониста альдостерона у петлевого диуретика: случайность или необходимость? Справочник поликлинического врача. М., 2010: 4.
  12. Laurent G.J. Dynamic state of collagen: pathwaus of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987; 252: 1–9.
  13. MSDS: TorsemideTablets.
  14. Преображенский Д.В., Некрасова Н.И., Хосева Е.Н. и др. Торасемид – эффективный петлевой диуретик для длительной терапии артериальной гипертонии. Кардиология, 2011; 4: 67–73.
  15. Fortuno A, Muniz P, Ravassa S, Rodriguez JA, et al. Torsemide inhibits angiotensin II induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension 1999; 34 (1): 138-43.
  16. EMA/383273/2015 Veterinary Medicines Division.
  17. Lee DY, Lee SJ, Lee MG Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats //2005-07-14, Int J Pharm., 298 (1): 38-46.
  18. Kim, E.J., Lee, M.G., 2003. Pharmacokinetics and pharmacodynamics of intravenous torasemide in mutant Nagase analbuminemic rats. Biopharm. Drug Dispos., 24, 27–35.
  19. Lee, D.Y., Kim, J.Y., Kim, Y.C., Kwon, J.W., et al. M.G., 2005. Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. Biopharm. Drug Dispos., 26, 173–182.
  20. Kim Y C, Oh E Y, Kim S H, Lee M G Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin //2005-11, Biopharm Drug Dispos., 26 (8): 371-8.
  21. Kim YC, Lee MG, Ko SH, Kim SH. Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. Biopharm Drug Dispos., 2004-0725 (5): 211-8.
  22. Lee AK, Kim EJ, Lee MG Effects of acute renal failure induced by uranylnitrate on the pharmacokinetics of intravenous torasemide in rats //: 2003, Res Commun Mol Pathol Pharmacol., 113-114:193-200.
  23. Sogame Y, Okano K, Hayashi K, Uchida T, et al. Urinary excretion profile of torasemide and its diuretic action in dogs // 1996-04, J Pharm Pharmacol., 48 (4): 375-9.
  24. Committee for Medicinal Products for Veterinary Use (CVMP) CVMP assessment report for UpCard (EMEA/V/C/003836/0000) EMA/383273/2015.
  25. Peddle GD, Singletary GE, Reynolds CA, Trafny DJ, et al. Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease //2012, J Vet Cardiol., 14 (1): 253-9.
  26. Remme W, Swedberg K.Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527–60.
  27. Sawsan A. Sadek, Laila A. Rashed, Amira M. Bassam, Eman S. Said. Effect of aliskiren, telmisartan, and torsemide on cardiac dysfunction in hypertensive rats. Journal of Advanced Research (2015) 6, 967–974.
  28. Yamanaga K, Uchida T, Kido H, Hayashi K, et al. Torsemide, but not furosemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44:64-5.
  29. Kim S, Hamaguchi A, Shinkawa T, Kato Y, et al. Molecular effects of M17055, furosemide and thiazide on cardiac hypertrophy of spontaneously hypertensive rats. J Pharmacol Exp Ther 1996;279 (2): 983–90.
  30. Tsutamoto T, Sakai H, Wada A, Ishikawa C et al. Torsemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2004; 44: 2252–3.
  31. Cosin J., Diez J. Torasemide in chronic heart failure: Results of the TORIC Study. Eur J Heart Fail 2002; 4:507–513.
  32. Hori Y, Takusagawa F, Ikadai H, Uechi M, et al. Effectsoforaladministrationoffurosemideandtorsemideinhealthydogs // 2007-10, Am J VetRes., 68(10):1058-63

Statistics

Views

Abstract - 15

PDF (Russian) - 2

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Pharmacy Formulas

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies